The Mussallem CHD Alliance participated in the 2025 3D Dartmouth Device Development Symposium, an annual forum that brings together leaders from clinical, industry, regulatory, academic, financial, and legal sectors to tackle critical challenges in medical device innovation and commercialization.
Held on September 25–26, 2025, in Woodstock, Vermont, this year’s symposium featured sessions and roundtable discussions focused on advancing technologies that improve patient care, with leaders from across the health innovation ecosystem in attendance.
MCA’s own contribution centered on a panel addressing Congenital Heart Defects (CHD) and the innovation needs of this patient population. Orin Herskowitz, President of MCA, presented insights on the Alliance’s commitment to accelerating CHD innovation and helping to bridge gaps between clinical needs, regulatory pathways, and investment attractiveness. The session was moderated by Dr. Mike Mack of Baylor Scott & White Health, who serves as an advisor to MCA.
MCA was privileged to share the panel with distinguished experts from leading institutions, including:
- Ami Bhatt, MD (American College of Cardiology)
- Rachel Evans Neubrander (U.S. Food and Drug Administration)
- Nina Goodheart (Medtronic)
- Daniel Gottlieb, MD (Broadview Ventures)
MCA’s engagement at the 3D Symposium underscores our ongoing commitment to convening and collaborating with stakeholders across the ecosystem to help patients survive and thrive, while propelling transformational technologies.